86 related articles for article (PubMed ID: 28668891)
1. Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy.
Fukagawa S; Yotsumoto F; Odawara T; Manabe S; Ishikawa T; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3891-3896. PubMed ID: 28668891
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
[TBL] [Abstract][Full Text] [Related]
3. BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
Miyamoto S; Yotsumoto F; Ueda T; Fukami T; Sanui A; Miyata K; Nam SO; Fukagawa S; Katsuta T; Maehara M; Kondo H; Miyahara D; Shirota K; Yoshizato T; Kuroki M; Nishikawa H; Saku K; Tsuboi Y; Ishitsuka K; Takamatsu Y; Tamura K; Matsunaga A; Hachisuga T; Nishino S; Odawara T; Maeda K; Manabe S; Ishikawa T; Okuno Y; Ohishi M; Hikita T; Mizushima H; Iwamoto R; Mekada E
BMC Cancer; 2017 Jan; 17(1):89. PubMed ID: 28143428
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
6. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.
Nam SO; Yotsumoto F; Miyata K; Fukagawa S; Odawara T; Manabe S; Ishikawa T; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2016 Jul; 36(7):3651-7. PubMed ID: 27354636
[TBL] [Abstract][Full Text] [Related]
8. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
9. Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer.
Izuchi D; Fukagawa S; Yotsumoto F; Shigekawa K; Yoshikawa K; Hirakawa T; Kiyoshima C; Ouk NS; Urushiyama D; Katsuda T; Miyata K; Ito T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Ito H; Shirota K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2018 Jul; 38(7):4347-4351. PubMed ID: 29970572
[TBL] [Abstract][Full Text] [Related]
10. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
14. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
16. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
18. Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer.
Miyata K; Yotsumoto F; Fukagawa S; Kiyoshima C; Ouk NS; Urushiyama D; Ito T; Katsuda T; Kurakazu M; Araki R; Sanui A; Miyahara D; Murata M; Shirota K; Yagi H; Takono T; Kato K; Yaegashi N; Akazawa K; Kuroki M; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3955-3960. PubMed ID: 28668900
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice.
Matsumoto Y; Miwa S; Zhang Y; Zhao M; Yano S; Uehara F; Yamamoto M; Hiroshima Y; Toneri M; Bouvet M; Matsubara H; Tsuchiya H; Hoffman RM
Oncotarget; 2015 May; 6(13):11369-77. PubMed ID: 25957417
[TBL] [Abstract][Full Text] [Related]
20. [HB-EGF is a promising target molecule for ovarian cancer].
Miyamoto S; Yagi H; Tanaka Y
Fukuoka Igaku Zasshi; 2004 Nov; 95(11):286-90. PubMed ID: 15717494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
